Enhancing Treatment Options for Autoimmune and Hematologic Diseases: The Potential of NKX019 and NKX101 TherapiesThe field of immunotherapy has witnessed significant advancements in recent years, offering new hope for patients with autoimmune diseases and hematologic malignancies. One promising avenue of research involves the development of engineered natural killer (NK) cell therapies. Nkarta, Inc., a biopharmaceutical company at the forefront of this research, has recently announced significant progress in its clinical trials evaluating NKX019 and NKX101 therapies. This article aims to discuss the potential of these therapies in the context of systemic lupus erythematosus (SLE) and relapsed or refractory a...

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis and Expands Pipeline to Address Autoimmune Indications

In a groundbreaking development, Nkarta, a leading biopharmaceutical company, has recently commenced the clinical trial of their innovative engineered NK cell therapy, NKX019, for the treatment of lupus nephritis. Ntrust-1 marks the first U.S.-based clinical trial investigating the application of this therapy in lupus nephritis patients. This article aims to provide an overview of the facts surrounding the initiation of this clinical trial, as well as highlight Nkarta s expansion of their pipeline to address additional autoimmune indications.Clinical Trial Details:The Ntrust-1 clinical trial, which focuses on evaluating the safety and efficacy of NKX019 in lupus nephritis patients, has now entered the patien...

An Innovative Leap: Nkarta’s Clinical Data on NKX101 Takes Center-Stage at the 2023 ASH Annual Meeting

Clinical Pioneers or Adventurers?nn,
San Francisco-based Nkarta, Inc., a company committed to creating pioneering treatments in the realm of cell therapies, has recently grabbed the spotlight at the American Society of Hematology (ASH) Annual Meeting and Exposition. Making significant strides in the clinical-stage biopharmaceutical industry, Nkarta, Inc. (Nasdaq: NKTX), came forward on December 9, 2023 to share the emerging data from its phase 1 clinical trial focusing on NKX101.

Targeting AML with NKX101nn
This trial is primarily focused on patients suffering from acute myeloid leukemia (AML), a high-risk form of blood and bone marrow cancer that counts for 1.3% of new cancer cases e...

NKTX's Stock Performance relative to it's Customers

NKTX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Nkarta Inc	213.80	0.00	-104.51	108
SUBTOTAL	0.00	0.00	0.00	-

Sources: Nkarta Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nkarta Inc’s corporate clients.
For your research, we’ve provided 9 tables on Nkarta Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.